Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11526 posts found.

valeant_logo_on_board

Valeant shares slide on SEC investigation announcement

March 1, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Philidore, Valeant, regulation

Shares at troubled Valeant plummeted some 20% Monday after the company said it was under investigation by the Securities and …
News

AstraZeneca licenses European rights to constipation drug for $70m

March 1, 2016 Manufacturing and Production, Sales and Marketing AstraZeneca, EU, Japan, Luke Miles, ProStrakan Group, constipation drug, moventig

AstraZeneca said on Tuesday it has agreed to licence rights to its constipation drug Moventig to Japan’s ProStrakan Group for …
News
ucb_logo

New epilepsy drug launches in UK

February 29, 2016 Medical Communications, Research and Development, Sales and Marketing Briviact, UCB Pharma, epilepsy

UCB Pharma’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS), with or without secondary …
News
roche_glass_building

FDA approves Roche’s Gazyva in follicular lymphoma

February 29, 2016 Research and Development, Sales and Marketing Levact, MabThera

Strong Phase III results have seen the US FDA approve Roche’s Gazyva (obinutuzumab) plus Levact (bendamustine) chemotherapy followed by Gazyva …
News
findacure

Drug repurposing can help tackle Rare Diseases, says charity

February 29, 2016 Medical Communications, Research and Development, Sales and Marketing rare diseases

On Rare Disease Day 2016, UK charity Findacure says existing drugs may hold the key to new treatments and repurposing …
News
boehringer_good

Boehringer launches IPF initiatives

February 29, 2016 Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev

Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …
News
afinitor

FDA approves new indication for Novartis’ Afinitor

February 29, 2016 Research and Development, Sales and Marketing Afinitor, Novartis

Novartis’ cancer drug Afinitor (everolimus) has been granted FDA approval in a new indication: for the treatment of adult patients …
News
eisai_logo

Eisai slams new Cancer Drugs Fund for delaying patient access

February 26, 2016 Research and Development, Sales and Marketing Cancer Drugs Fund, Eisai, Lenvima

Eisai has aimed strong criticism at NHS England for its approval of reforms to the Cancer Drugs Fund, calling the …
News
boehringer_good

Boehringer’s OFEV slows IPF disease progression by half in trials

February 26, 2016 Research and Development, Sales and Marketing Boehringer Ingelheim, IPF, ofev

Boehringer Ingelheim has revealed pooled analysis data from three trials, showing that its drug OFEV significantly reduces the risk of …
News

INTERVIEW: AstraZeneca on the Cancer Drugs Fund reforms

February 26, 2016 Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund

Greg Rossi, head of the Oncology Business Unit, AstraZeneca UK and Ireland, and the company’s market access team, spoke to …
Feature
msd

MHRA approves new indication for MSD’s Ezetrol

February 26, 2016 Medical Communications, Research and Development, Sales and Marketing MHRA, MSD, NICE, ezetrol

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for MSD’s Ezetrol (ezetimibe), making it …
News
medicines_patent_pool2

The Medicines Patent Pool – five years on

February 25, 2016 Research and Development, Sales and Marketing

Introduction The Medicines Patent Pool (MPP) was founded five years ago as a program to improve access to affordable and …
Feature
gilead-sciences

Gilead announces HIV regimen trial results

February 25, 2016 Medical Communications, Research and Development, Sales and Marketing Gilead Sciences

Gilead Sciences has reported 48-week Phase III trial results suggesting fixed-dose Emtriva and tenofovir alafenamide (F/TAF) combinations matched its Truvada …
News
talc

J&J fined $72 million in talc cancer case

February 24, 2016 Research and Development, Sales and Marketing Johnson & Johnson

A Missouri jury has ruled that Johnson & Johnson must pay $72 million to the family of an Alabama woman, …
News
howard_schiller_valeant

Valeant likely to restate financial results after Philidore review

February 23, 2016 Manufacturing and Production, Medical Communications, Sales and Marketing Howard Schiller, Philidore, Valeant

Valeant says it is likely to restate its financial results for the last two years, in the wake of the …
News
The Gateway to Local Adoption Series

Latest content

China approves fruquintinib combination for kidney cancer

May 29, 2026

BIOTRONIK, Charité and GHCF launch digital cardiology partnership

May 28, 2026

Endometriosis study begins recruitment in UK hospitals

May 28, 2026

MHRA authorises donidalorsen for hereditary angioedema prevention

May 27, 2026

Partnership aims to expand early access to medicines

May 26, 2026